Table of contents
February 2007 Vol 6 No 2
In this issue
p95 | doi:10.1038/nrd2258
Editorial: Same old story?
p97 | doi:10.1038/nrd2259
News and Analysis
2006 drug approvals: finding the niche | PDF (299 KB)
p99 | doi:10.1038/nrd2247
News in Brief
PDUFA recommendations highlight drug safety | Company registration of clinical trials improves | Bristol–Myers Squibb and AstraZeneca collaborate on potential diabetes drugs | Cheaper biologics for hepatitis C? | Abbott to sell major parts of diagnostics business to General Electric | Reorganizations at the FDA | PDF (295 KB)
p102 | doi:10.1038/nrd2248
Patent watch
Supreme Court sides with MedImmune | Ethical medicine or clever IP dodge? | Abbott forced to stop selling HCV diagnostic | Heart failure | PDF (186 KB)
p104 | doi:10.1038/nrd2249
An Audience With
Carlo Incerti | PDF (99 KB)
p106 | doi:10.1038/nrd2250
From the analyst's couch
Clinical forecasting in drug development | PDF (166 KB)
p107 | doi:10.1038/nrd2246
Fresh from the Pipeline
Sitagliptin | PDF (176 KB)
p109 | doi:10.1038/nrd2245
Research Highlights
Anticancer drugs: Escaping inhibition | PDF (125 KB)
p111 | doi:10.1038/nrd2253
Angiogenesis: Less is more | PDF (120 KB)
p112 | doi:10.1038/nrd2252
HIV: Rat to the rescue | PDF (101 KB)
p112 | doi:10.1038/nrd2254
Malaria: New drug lead from Madagascar's rainforests | PDF (162 KB)
p113 | doi:10.1038/nrd2256
Stem cells: Ethical sourcing? | PDF (92 KB)
p114 | doi:10.1038/nrd2255
In brief
Nanotechnology | Analgesia | Anticancer Drugs | Neurodegenerative Disease | PDF (102 KB)
p114 | doi:10.1038/nrd2257
Perspectives
Opinion
Why is cancer drug discovery so difficult?
Alexander Kamb, Susan Wee & Christoph Lengauer
p115 | doi:10.1038/nrd2155
Oncology has a higher rate of attrition in clinical development than most other therapeutic areas. Lengauer and colleagues discuss the factors responsible, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.
Preclinical safety testing of monoclonal antibodies: the significance of species relevance
Kathryn Chapman, Nick Pullen, Mark Graham & Ian Ragan
p120 | doi:10.1038/nrd2242
The therapeutic success of monoclonal antibodies has led to a steep rise in the use of non-human primates for preclinical safety testing. Chapman and colleagues report from a recent workshop on this topic, and discuss the economic, scientific and ethical questions raised by this development.
Reviews
Drug discovery for heart failure: a new era or the end of the pipeline?
David M. Kaye & Henry Krum
p127 | doi:10.1038/nrd2219
There is a major need for better therapies for many patients with heart failure, but late-stage clinical failures of several potential drugs have reduced the impetus of drug development in this field. Kaye and Krum review emerging agents and molecular targets for heart failure, and highlight key issues that need to be addressed to improve the chances of successfully developing new drugs.
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Amin Rostami-Hodjegan & Geoffrey T. Tucker
p140 | doi:10.1038/nrd2173
Being able to predict the individual effects of drugs on different patients in a population could lead to safer, more effective medicines. The authors discuss the development of algorithms that could enable the testing of drugs in virtual patient populations based on in vitro data.
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Ching-Hon Pui & Sima Jeha
p149 | doi:10.1038/nrd2240
New therapeutic strategies are needed to improve the cure rate and quality of life in patients with acute lymphoblastic leukaemia. In this Review, Pui and Jeha discuss emerging new treatments that could improve the clinical outcome for these patients.
Careers and Recruitment
Corrigendum: Avoiding premature licensing
Mark Kessel & Sam Hall
| doi:10.1038/nrd2260
Corrigendum: Drugs, their targets and the nature and number of drug targets
Peter Imming, Christian Sinning & Achim Meyer
| doi:10.1038/nrd2261
Corrigendum: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm, Christopher Carter, Mark Lynch, Timothy Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov & Susan Kelley
| doi:10.1038/nrd2262
Corrigendum: Multi-targeting by monotherapeutic antibacterials
Lynn L. Silver
| doi:10.1038/nrd2263
